A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks.

Bearing in mind that renal impairment is among the worst complications of ANCA-associated vasculitis (AAV), researchers have identified four different trajectories of kidney function over time in AAV patients, with implications for personalized treatment, as well as future research.

In a cohort of 225 patients, 20 experienced rapid decline, 82 showed stable impairment, 129 had stable near-normal function, and 24 showed increases in kidney function, reported Zachary S. Wallace, MD, MSc, of Massachusetts General Hospital in Boston, and colleagues.